Inhaled drug delivery is a crucial route for administering pharmaceuticals, particularly for respiratory conditions like asthma, chronic obstructive pulmonary disease (COPD), and infectious diseases. This route offers several advantages, including rapid onset of action, localized drug delivery to the affected areas of the respiratory system, and reduced systemic side effects. In preclinical research, inhaled drug delivery allows scientists to investigate the efficacy, safety, and pharmacokinetics of novel compounds, as well as to model and explore the mechanisms underlying respiratory disease.
SCIREQ offers turn-key solutions for advancing preclinical research in the field of inhaled drug delivery:
Inhalation Delivery of Interferon-λ-Loaded Pulmonary Surfactant Nanoparticles Induces Rapid Antiviral Immune Responses in the Lung. (2024). Gil., C.H., et al. Applied Materials & Interfaces, https://doi.org/10.1021/acsami.3c13677
Development of alternative in vitro and ex vivo models for testing of inhalable antibiotics – InhalAb.”Wronski, S., et al. (2020). Models of Lung Disease Workshop 2020, Hannover (Germany)
Ventilator Assisted Drug Delivery (VAAD) is a hybrid between nose-only inhalation and intratracheal instillation. The approach consists in intubating the subject and using optimized computer-controlled ventilation profiles to administer the inhaled compound deep into the subject’s lungs, over several breaths. This strategy minimizes subject-to-subject variability, and fosters a highly homogenous aerosol deposition within the lung. It further allows researchers to measure the lung function of the subject prior to and post administration. VAAD can therefore be used for drug delivery and disease modelling (e.g. for IPF studies with Bleomycin).
The expoCube is a novel Air Liquid Interface (ALI)/Transwell in vitro exposure system which permits highly reliable and effective deposition of aerosols onto cells and tissues. This exposure takes advantage of Thermophoresis, which guides small particles and gas onto the target tissue through a temperature gradient and increases the deposition rate from 2% to ~40%.
Developing Inhaled Cannabis Product Methods for in vitro Toxicological Assessment. Wilson, E., et al (2023). SOT 2023
A novel microfluidic platform for pulmonary nanoparticle exposure .Kiss, F.M et al. (2021). 11th edition of the World Congress on Alternatives and Animal Use in the Life Sciences, virtuel congress, Maastricht, Netherlands
“Intermittent exposure to whole cigarette smoke alters the differentiation of primary small airway epithelial cells in the air-liquid interface culture”, Gindele, J.A, et al. (2020). Scientific Reports volume 10, Article number: 6257
Cigarette smoke exposure disrupts epithelial barrier function and impairs antiviral immune response to influenza infection ex vivo. Böhlen, S. et al. (2020). Models of Lung Disease Workshop 2020, Hannover (Germany)
A recent publication by Boucher et al (2024) streamlines this process of quantifying airway constriction in Precision Cut Lung Slices (PCLS) by using the new physioLens automated solution for physiology and image analysis. This new solution enables researchers to conduct high-throughput screening of airway constriction with unprecedented precision and efficiency.
Idiopathic pulmonary fibrosis (IPF) remains a devastating condition with limited treatment options, often leading to a grim prognosis. However, a recent study by Milman-Krentsis (2024) offers a beacon of hope, demonstrating the potential of lung cell transplantation as a therapeutic intervention for lung fibrosis.
The incidence of landscape fires has been rising globally, leading to increased exposure to landscape fire smoke (LFS) among millions of people. The inhalation of particulate matter (PM) from LFS is associated with adverse respiratory and cardiovascular outcomes.
Recent advances in the fight against severe acute inflammatory lung diseases, including COVID-19, have revealed a promising new approach to treating pulmonary hyperinflammation and long-term lung damage such as fibrosis.
Recent advances in the fight against severe acute inflammatory lung diseases, including COVID-19, have revealed a promising new approach to treating pulmonary hyperinflammation and long-term lung damage such as fibrosis.
Tuberculosis and Human Immunodeficiency Virus are major global health threats. Their interaction worsens disease severity, as HIV reduces CD4+ T cells, making individuals more vulnerable to TB.
Save time evaluating SCIREQ equipment by having a SCIREQ Application Specialist conduct a custom
literature research. Researchers will receive an email report showing SCIREQ publications relevant to their specific application research area, along with custom equipment recommendations and commentary.
